As of 2025-09-15, the EV/EBITDA ratio of Esperion Therapeutics Inc (ESPR) is -22.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ESPR's latest enterprise value is 784.76 mil USD. ESPR's TTM EBITDA according to its financial statements is -35.31 mil USD. Dividing these 2 quantities gives us the above ESPR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 14.0x | 10.8x |
| Forward P/E multiples | 12.7x - 22.0x | 17.4x |
| Fair Price | (2.31) - (0.72) | (1.86) |
| Upside | -181.3% - -125.2% | -165.5% |
| Date | EV/EBITDA |
| 2025-09-12 | -22.22 |
| 2025-09-11 | -21.94 |
| 2025-09-10 | -20.85 |
| 2025-09-09 | -20.51 |
| 2025-09-08 | -20.34 |
| 2025-09-05 | -21.31 |
| 2025-09-04 | -20.45 |
| 2025-09-03 | -19.88 |
| 2025-09-02 | -19.25 |
| 2025-08-29 | -18.68 |
| 2025-08-28 | -18.63 |
| 2025-08-27 | -18.46 |
| 2025-08-26 | -18.51 |
| 2025-08-25 | -18.28 |
| 2025-08-22 | -18.40 |
| 2025-08-21 | -18.17 |
| 2025-08-20 | -17.71 |
| 2025-08-19 | -17.66 |
| 2025-08-18 | -18.00 |
| 2025-08-15 | -17.71 |
| 2025-08-14 | -17.83 |
| 2025-08-13 | -17.08 |
| 2025-08-12 | -16.23 |
| 2025-08-11 | -16.54 |
| 2025-08-08 | -16.69 |
| 2025-08-07 | -16.34 |
| 2025-08-06 | -16.97 |
| 2025-08-05 | -15.26 |
| 2025-08-04 | -14.52 |
| 2025-08-01 | -14.00 |
| 2025-07-31 | -14.12 |
| 2025-07-30 | -14.06 |
| 2025-07-29 | -14.40 |
| 2025-07-28 | -15.09 |
| 2025-07-25 | -14.63 |
| 2025-07-24 | -14.52 |
| 2025-07-23 | -13.60 |
| 2025-07-22 | -12.97 |
| 2025-07-21 | -12.57 |
| 2025-07-18 | -12.69 |
| 2025-07-17 | -13.09 |
| 2025-07-16 | -12.40 |
| 2025-07-15 | -12.46 |
| 2025-07-14 | -12.75 |
| 2025-07-11 | -12.80 |
| 2025-07-10 | -13.09 |
| 2025-07-09 | -13.03 |
| 2025-07-08 | -12.69 |
| 2025-07-07 | -12.35 |
| 2025-07-03 | -12.69 |